<DOC>
	<DOCNO>NCT02787915</DOCNO>
	<brief_summary>This trial evaluate safety effectiveness autologous type-1 polarize dendritic cell vaccine ( patient ' autologous DC1s load multiple antigen CTL epitope peptide complex ) , radical resection patient stage III-IV renal cell carcinoma . Autologous cytotoxic T lymphocytes ( CTL ) induce type-1 polarized dendritic cell ( DC1 ) load MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptide .</brief_summary>
	<brief_title>DC1s-CTL Cellular Therapy Renal Cell Carcinoma</brief_title>
	<detailed_description>All participant judge RCC consider able conduct apheresis . Immunotherapy regimen include subcutaneous injection ( 3million cell ) DC1 vaccines intravenous infusion CTL cell . On day 0 , participant conduct apheresis 50-60ml . PBMCs separate paiticipants density gradient centrifugation . The adherent cell initiate DC follow particular combination cytokine promote DC type-1 polarization . On day 6 , synthetic CTL epitope peptides added culture autologous DCs another 24h . Then one half DC1s resuspend 1ml normal saline clinical multi-point injection near lymph node . The remain half cocultured autologous T cell another 7 day induce antigen-specific CTL cell . The applied TAAs include MAGE-3/ MAGE-4/ survivin/ her2 /ect . On day 14 , quality inspection qualify , CTL cell harvest resuspend 100ml normal saline 2 % autologous plasma clinical intravenous infusion , day 3 day . In order avoid overlap experimental immunotherapy potential adjuvant chemotherapy , chemotherapy may start least 2 week completion cycle immunotherapy . The 2nd cycle immunotherapy may start least 4weeks completion chemotherapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Patients histologically confirm stage IIIIV renal malignancy ; The patient underwent radical operation RCC within 8 week enrollment ; Must normal marrow hematopoiesis function define : Hemoglobin≥90g/L , WBC &gt; 4000/mm3 , Absolute Neutrophil Count ( ANC ) ≥1500/µL , Platelet≥ 100,000/µL , Must normal important organ function define : Total bilirubin≤1.5 x institutional upper limit normal ( ULN ) , AST ( SGOT ) ALT ( SGPT ) ≤2.5x ULN , ALP≤1.5x ULN ; BUN Creatinine &lt; 1.5x ULN , Creatinine clearance ≥80mL/min . life expectancy≥3 month ; No serious heart , liver kidney organ dysfunction ; Quality life score ( Karnofsky performance score ) ≥60 ; Patients must able understand willing sign write informed consent document . Prior allergic reaction hypersensitivity cytokine ( eg.IL2 ) ; Patients systemic local infection require antiinfectious treatment ; Patients currently treat systemic immunosuppressive agent , include steroid , Patients active autoimmune disease history transplantation require steroid treatment ; Tested positive HIV ; Pregnant lactate woman Patients important organ dysfunction ; Any reason , opinion investigator , contraindicate patient participates study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>dendritic cell</keyword>
	<keyword>cytotoxic T lymphocyte</keyword>
	<keyword>DC vaccine</keyword>
</DOC>